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Background: Osteoporosis is a leading cause of morbidity in
patients aﬀected by b-thalassemia major or intermediate; we aimed
to assess the association between demineralization observed in
young thalassemic patients.
Methods: A total of 88 patients with b-thalassemia were recruited
at Microcitemia Center of Taranto Hospital under the Prevention
Osteoporosis and Fractures research project from 2008 to 2010. All
the patients were screened with both dual energy x-ray absorpti-
ometry (DXA) and quantitative ultrasound (QUS). T score and
Z score values were obtained for each subject.
Results: The overall prevalence of demineralization was 84% with
DXA and 70% with QUS, whereas normality was found in 16% of
patients screened with DXA and in 30% of cases with QUS.
Hypogonadism, hypothyroidism, diabetes mellitus, hepatitis-B,
and the presence of previous fragility fractures were signiﬁcantly
associated with the demineralization status (lower T scores values)
both with DXA and QUS.
Conclusion: Our data conﬁrm that DXA and QUS examinations
are both useful for detecting bone demineralization in thalassemic
patients.
Key Words: osteoporosis, thalassemia, hypogonadism, fractures,
ultrasound (QUS)
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b-Thalassemia is a heterogenous family of inheriteddisorders aﬀecting hemoglobin synthesis. It is charac-
terized by the complete absence or reduced synthesis of the
b chain of hemoglobin, resulting in increased, but ineﬀec-
tive, erythropoiesis. The b-thalassemia phenotypes are
variable, ranging from severe conditions requiring blood
transfusions (thalassemia major [TM]) to milder forms
(intermediate thalassemia [TI]). Patients aﬀected by TM
always present a severe microcytic and hypochromic ane-
mia, associated with hepatosplenomegaly, and usually
come to medical attention within the ﬁrst 2 years of life.
Treatment with regular blood transfusions and chelation
therapy, which is aimed at reducing transfusion-induced
iron overload, allows normal growth and development of
these children. This therapeutic approach has extended
patients’ life expectancy up to the age of 30 or 40 years,
with a substantially improved survival and quality of life.1
Subjects presenting TI show a later onset of the dis-
ease, characterized by milder anemia rarely requiring blood
transfusion. These patients also present liver and spleen
enlargement, typical bone modiﬁcations, and mild to
moderate jaundice.2 Current epidemiological data show
that approximately 7% of the global population present
genes associated with hemoglobin disorders (healthy carrier
of the disease). It is estimated that 300,000 to 500,000
children suﬀering from TM are delivered annually, 80% of
who are living in developing countries.3 As the longevity of
patients with TM increases, osteoporosis has emerged as an
important cause of morbidity and disability in adult
patients.4 The etiology of bone diseases in patients with
thalassemia is more complex than in individuals without
thalassemia. Factors such as anemia, massive ineﬀective
erythropoiesis, bone marrow expansion with thinning of
cortical bone, endocrine dysfunction, iron overload, des-
ferrioxamine toxicity, metabolic factors (ie, deﬁciencies in
calcium, vitamin D, and zinc), inadequate physical activity,
and genetic factors may all play a role in the reduction of
bone mass in these patients. In the last decade, the presence
of osteopenia and osteoporosis in thalassemic patients
receiving all the current gold standard treatments for this
disease has been described in diﬀerent studies, showing a
high prevalence of up to 50%.5,6 Two main techniques are
commonly used for evaluation of bone mineral density and
fragility fracture risk: dual energy x-ray absorptiometry
(DXA) bone densitometry is the “gold standard” method
for diagnosis of osteoporosis, with this condition being
deﬁned by a reduction of bone mineral density (BMD)
>2.5 SD below the values observed in healthy young
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subjects (T score <2.5 SD). DXA has been widely
accepted as a reference method for BMD measurement in
adults and in pediatric subjects.7 However, it seems that
other factors, in addition to BMD reduction, such as elas-
ticity and bone microarchitectural bone characteristics are
also important in determining bone fragility. Therefore,
diﬀerent quantitative ultrasound (QUS) methods have been
developed for the assessment of fracture risk.8,9 QUS
measured at the phalanx is a novel kind of noninvasive,
radiation-free, and portable method that can be used
extensively to get both qualitative and quantitative infor-
mation.10–12 As comorbidities (ie, hypogonadism, hypo-
thyroidism, and other illnesses) might play a relevant role in
inducing bone demineralization, the aim of this study was
to assess the ability of DXA and QUS to evaluate fracture
risk in thalassemic patients, with particular focus on the
eﬀect of age and concurrent diseases on T score values.
MATERIALS AND METHODS
Within the Prevention Osteoporosis and Fractures
Project, which is an innovative disease management pro-
gram aimed at preventing osteoporotic fractures in the
Salento region, we have enrolled 88 young thalassemic
patients being followed up at SS Annunziata Hospital in
Taranto.
Of the 88 enrolled patients, 42 (48%) were male
patients (aged 22 to 69 y; mean age: 34.1 y; SD±7.9), and
46 (52%) were female patients (aged 13 to 48 y; mean age:
34.5 y; SD±6.7). The majority of patients was aﬀected by
TM (n=58; 66% of the sample), whereas the remaining 30
patients (34% of the sample) were aﬀected by TI. These 2
groups were following diﬀerent kinds of treatments based
on the severity of the disease: patients with TM assumed
iron-chelating therapy (desferrioxamine, deferasirox, or
deferiprone) every day and underwent blood transfusion
2 times per month. TI patients followed a variable ther-
apeutic regimen based on daily iron-chelating therapy, with
blood transfusion being infrequently necessary.
For all patients, QUS measurements at the phalanx
were performed using ultrasound densitometer DBM Sonic
1200 Bone Proﬁler (IGEA S.r.l.; Carpi, MO, Italy). DXA
measurements at the lumbar spine (L1-L4) were also
obtained for all patients by using Hologic QDR 4000
machine (Bedford, MA). All measurements were performed
between 2008 and 2010, and informed consent was obtained
from all the patients. T score and Z score values were
obtained for all patients. For the DXA method, osteopo-
rosis and osteopenia were deﬁned according to the World
Health Organization deﬁnitions (osteoporosis:
T score <2.5; osteopenia: T score between >2.5 and
<1; normal: T score >1).13 For QUS of the phalanx,
diﬀerent cutoﬀ values have been directly provided by the
manufacturer (osteoporosis: T score <3.2; osteopenia:
T score between >3.2 and <1; normal: T score
>1).14 Calibration of QUS densitometer was carried out
daily using manufacturer’s veriﬁcation phantom for quality
control and assurance. T score values obtained with both
methods (DXA and QUS) were correlated to age, sex, body
mass index, type of thalassemia (TM or TI), previous fra-
gility fractures, and presence of the following concurrent
diseases: diabetes, hypothyroidism, hypogonadotrophic
hypogonadism, and hepatitis (HBV). Fragility fractures
were deﬁned as resulting from low-energy trauma at dif-
ferent skeletal sites (ie, hip, humerus, vertebrae, wrist, leg,
and ankle). Fractures that occurred at workplace or as a
consequence of car accidents, as well as fractures of ﬁngers and
big toe, were excluded from statistical analyses because they
were likely to be related to high-energy trauma. Statistical
analyses were performed using STATA 11.0 (StataCorp LP,
College Station, TX). Paired and unpaired Student t test was
used to compare the comparisons. Ratios were compared by
the w2 or Fischer exact test. Linear regressions were performed
to evaluate the eﬀect of age, height, and weight on T scores
obtained with both methods.
RESULTS
Nine of 88 patients (10% of the sample) presented a
previous diagnosis of diabetes mellitus, whereas 10 patients
had hypothyroidism (11%), 43 were aﬀected by HBV
(49%), and 52 (59%) presented hypogonadotrophic hypo-
gonadism. There were 23 (26%) patients with a previous
fragility fracture.
Table 1 shows the characteristics of the study pop-
ulation. Patients’ height and weight were higher in the male
than in the female patients, with this diﬀerence reaching
statistical signiﬁcance (P<0.05). T score values did not
show any statistically diﬀerence when adjusted by height
and weight (P=0.487 and 0.283, respectively). All the
other examined parameters showed no correlation with sex.
In Table 2, we report T score and Z score values obtained
TABLE 1. Characteristics of Study Population (n= 88)
Males (n=42) Females (n=46)
Mean SD Min Max Mean SD Min Max P
Height (cm) 168 7 153 187 158 7 141 177 <0.05
Weight (kg) 65 9.0 47 84 56 9.6 40 85 <0.05
BMI (body mass index) 23.3 2.7 17.7 29.1 22.7 3.4 17.8 33.2 >0.05
Age_QUS (y) 34.0 7.9 22 69 34.5 6.7 13 48 >0.05
T score QUS 1.9 1.6 6.4 0.49 1.5 0.89 3.91 0.29 >0.05
Z score QUS 1.7 1.6 6.36 1.99 1.44 0.95 3.91 0.34 >0.05
Age_DXA (y) 33.0 8.0 19 67 32.9 6.7 2 47 >0.05
T score DXA 2.7 1.3 5.9 0.1 2.3 1.3 4.4 1 >0.05
Z score DXA 2.8 1.2 5.7 0.1 2.2 1.3 4.4 1.1 <0.05
Age at start of iron-chelating therapy (y) 4.6 3.4 1 20 5.5 4.8 1 28 >0.05
Age at start of transfusion (mo) 2.2 3.8 0.2 24 2.1 2.9 0.3 13 >0.05
DXA indicates dual energy x-ray absorptiometry; QUS, quantitative ultrasound.
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by using both DXA and QUS according to the type of
thalassemia, presence of hypothyroidism, hypogonado-
trophic hypogonadism, diabetes, HBV, and previous fra-
gility fractures. The comparison of T score and Z score
values between TM and TI patients did not show statisti-
cally signiﬁcant diﬀerences for both techniques.
The 52 subjects suﬀering from hypogonadotrophic
hypogonadism showed lower T score values compared with
the 36 patients not aﬀected by hypogonadism. Lower values
were observed also in case of hypothyroidism, although the
number of patients (n=10) is too little to extend this
observation. Patients with HBV (almost 50% of the sam-
ple) showed lower T score values compared with patients
not aﬀected by HBV.
Similarly, also diabetes was associated with low T
score values, although no statistical signiﬁcance was
reached due to the small number of subjects aﬀected
(n=9). As reported in Table 3, both DXA and QUS were
equally able to detect the demineralization status in almost
all patients with previous fragility fractures (91% for DXA
and 83% for QUS).
The overall prevalence of osteopenia and osteoporosis
deﬁned by DXA and QUS are presented in Tables 4 and 5,
respectively. Using DXA, 60% of the male patients (25/42)
and 45% of the female patients (21/46) were found to be
osteoporotic, whereas osteopenia was reported in 28% of
male patients (12/42) and in 35% of female patients (16/46).
Overall, osteoporosis showed a global prevalence of 52%
(46/88) by DXA and only 10% by QUS (9/88), whereas
osteopenia was found in 32% (28/88) and in 60% (53/88) of
cases using DXA or QUS, respectively. Up to 12% of male
and 20% of female patients presented DXA T score values
higher than 1 SD (normality). Normal ﬁndings were more
frequent when QUS was used (28% of male patients: 12/42;
31% of female patients: 14/46). When performing the
Fisher exact test, there were no diﬀerences in the ratios
between the male and female patients both for DXA
(P=0.420) and QUS (P=0.184).
DISCUSSION
This is the ﬁrst study addressing the issue of DXA and
QUS ability to detect fragility fractures and concurrent
pathologies in thalassemic patients. In a previous study
aimed at comparing DXA and quantitative computed
tomography (QCT), Mylona and colleagues observed a
strong diﬀerence in the prevalence of osteopenia and
osteoporosis in patients with b-thalassemia according to the
technique used. In this study we observed a diﬀerent
prevalence of osteoporosis for DXA and QUS.15 The
classiﬁcation of our patient into normal, osteopenic, and
osteoporotic categories is exclusively based on T score
TABLE 2. T Scores Obtained With Both Methods According to Different Clinical Variables
T Score QUS Z Score QUS T Score DXA Z Score QUS
Mean SD Mean SD Mean SD Mean SD n
Type of thalassemia
Major 1.76 1.38 1.62 1.39 2.64 1.35 2.61 1.38 58
Intermediate 1.56 1.08 1.42 1.10 2.27 1.07 2.20 1.11 30
Hypothyroidism
Yes 2.24 1.23 1.86 0.78 2.60 0.84 2.77 1.11 10
No 1.62 1.29 1.51 1.35 2.51 1.32 2.43 1.33 78
Hypogonadotrophic hypogonadism
Yes 2.03 1.26 1.92 1.18 2.83 1.22 2.80 1.26 52
No 1.21 1.17 1.01 1.29 2.06 1.22 2.01 1.24 36
Diabetes
Yes 2.70 1.45 2.65 1.45 2.80 0.93 2.71 0.94 9
No 1.58 1.23 1.42 1.23 2.48 1.30 2.45 1.34 79
Hepatitis-B
Yes 1.95 1.28 1.85 1.19 2.98 1.02 2.96 1.09 43
No 1.45 1.26 1.26 1.35 2.07 1.33 2.00 1.33 45
Previous fractures
Yes 1.72 1.30 1.67 1.29 2.97 1.28 2.93 1.10 23
No 1.68 1.29 1.51 1.31 2.35 1.13 2.31 1.33 65
DXA indicates dual energy x-ray absorptiometry; QUS, quantitative ultrasound.
TABLE 3. Ability of DXA and QUS to Detect Patients With Previous Fragility Fracture
DXA, n (%) QUS, n (%)
Previous Fractures Normal (%) Demineralization (%) Normal (%) Demineralization (%)
Yes 2 (9) 21 (91) 4 (17) 19 (83)
No 12 (18) 53 (82) 22 (34) 43 (66)
Total 14 (16) 74 (84) 26 (30) 62 (70)
DXA indicates dual energy x-ray absorptiometry; QUS, quantitative ultrasound.
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values. Osteoporosis and osteopenia are nowadays highly
prevalent in patients aﬀected by TM or TI, with increased
patient survival and multifactorial pathogenesis being
responsible for that (iron inclusions in the bones, desfer-
rioxamine-induced bone dysplasia, ineﬀective erythropoi-
esis, and multiple endocrine dysfunctions).
Hormonal deﬁciency is an important cause of demin-
eralization in TM and TI, as lower testosterone levels in
men are associated with low BMD and an increased inci-
dence of spine and hip fractures.16 It is known that ado-
lescents with hypogonadism do not achieve optimal bone
mass.17 In addition, delayed puberty, hypoparathyroidism,
and hypothyroidism have been proposed as causes of
reduction in BMD.18,19 Another metabolic/endocrine dis-
order such as diabetes mellitus has been reported to neg-
atively inﬂuence bone density in thalassemic subjects,20
although a diﬀerent study has not conﬁrmed this observa-
tion.15 The crucial role of hormonal regulation is conﬁrmed
by the high number of thalassemic patients with hypo-
gonadotrophic hypogonadism (52/88) showing low T scores
by both DXA and QUS. The prevalence of osteoporosis
and osteopenia with DXA was 52% and 32%, respectively.
These results are consistent with those of previous stud-
ies.20,21 In contrast with other reports,15,22,23 we found a
relevant diﬀerence between sexes. However, this ﬁnding was
reported by several authors.24 Although DXA sensitivity
for the detection of osteoporosis was higher, both DXA
and QUS were able to detect the demineralization status
(osteopenia or osteoporosis) in the vast majority of subjects
with previous fragility fractures.
With both techniques, osteoporosis was found to be
more frequent in the male than in the female patients (60%
vs. 45% by DXA, and 17% vs. 4% by QUS), whereas
osteopenia was more prevalent among the female compared
with the male patients (35% vs. 28% by DXA and 65% vs.
55% by QUS). Normal T score values (> 1 SD) were
more frequently obtained by QUS (26 patients of 88; 30%
of the sample) than with the DXA method (14 patients of
88; 10% of the sample). Data obtained with the QUS
technique were particularly interesting, showing only a 10%
prevalence rate for osteoporosis, and a higher number of
osteopenic patients (60%) compared with DXA. This result
places the QUS method in an intermediate position between
DXA and QCT, which identify the majority of patients as
osteoporotic and normal,15,25,26 respectively. In their direct
comparison study, Mylona et al15 have reported 44% and
6% of patients as osteoporotic with DXA (normal ﬁndings
only in 4% of the subjects) and QCT (54% of normal
ﬁndings), respectively. DXA and QCT methods provide a
measure of BMD, which is currently considered the best
predictor of osteoporotic fractures.27 However, these tech-
niques are able to explain only 60% to 80% of the varia-
bility in bone strength, and it has been demonstrated that
other mechanical aspects of the bone are important in
determining fracture risk. These factors include micro-
architectural parameters and geometric and elastic prop-
erties of bone tissue, which cannot be assessed using
DXA.28 QUS techniques have been developed over the past
10 years to determine bone quality and the state of the
skeleton on the basis of various studies suggesting how
sonographic parameters are able to provide information on
bone density and structure, including elastic properties.29
Many authors report that low DXA values do not
reﬂect the behavior of vertebrae under stress conditions,30
thus suggesting that BMD represents only 1 factor involved
in determining bone strength, and that bone quality is
independent from mineral density. Despite the lack of
speciﬁc correlation studies between DXA and QUS ﬁnd-
ings, large prospective studies, carried out both in the eld-
erly and early postmenopausal women, indicate that these 2
techniques are equally able to predict patients at risk for
future fragility fractures.31–33 The discriminatory power in
classifying individuals with or without vertebral fractures
was tested in cross-sectional studies using diﬀerent QUS
methods, including QUS of the phalanx, and DXA in a
sample of older postmenopausal women.34 In addition, a
multicentric study assessed the performance of 5 diﬀerent
ultrasound devices and their association with prevalent
vertebral fractures compared with DXA in a group of
European women.35 In addition, this study showed that
QUS ﬁndings are similar to DXA femoral BMD in iden-
tifying subjects with prevalent vertebral fractures.
According to our study, the classiﬁcation of b-tha-
lassemic subjects as osteoporotic or osteopenic yields vari-
able results, and this depends on the technique used. If we
consider DXA to be more speciﬁc, most of the patients
should be classiﬁed as osteopenic and/or osteoporotic,
a ﬁnding not in accordance with the low incidence of pre-
vious fragility fractures observed in our sample. Our study
demonstrates a “proﬁtable” correlation between QUS and
DXA measurements in thalassemic patients. In summary,
our study showed that the ability of the QUS method to
detect patients with previous fracture outside the range of
normal T scores is high, as much as that of DXA. High
prevalence of osteoporosis and osteopenia among patients
with thalassemia requires more attention to therapeutic
approaches for the prevention and treatment of these
skeletal disorders. Osteoporosis is a progressive disease that
can start in early childhood in this kind of patients.
Therefore, prevention and early diagnosis become partic-
ularly important, as well as treatment of the established
disease. Annual screening of adolescent thalassemic
TABLE 4. Prevalence of Osteopenia and Osteoporosis Derived by
the DXA Method
Normal
T Scores
>1 (%)
Osteopenia
T Scores 1
to 3.2 (%)
Osteoporosis
T Scores
<3.2 (%)
Males 5 (12) 12 (28) 25 (60)
Females 9 (20) 16 (35) 21 (45)
Total 14 (16) 28 (32) 46 (52)
P=0.420 (Fisher exact test).
DXA indicates dual energy x-ray absorptiometry.
TABLE 5. Prevalence of Osteopenia and Osteoporosis Derived by
the QUS Method
Normal
T Score
>1 (%)
Osteopenia
T Score
1 to 3.2 (%)
Osteoporosis
T Score
<3.2 (%)
Males 12 (28) 23 (55) 7 (17)
Females 14 (31) 30 (65) 2 (4)
Total 26 (30) 53 (60) 9 (10)
P=0.184 (Fisher exact test).
QUS indicates quantitative ultrasound.
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patients and correction of endocrine factors by replacement
therapy might be a promising approach to prevent osteo-
porosis in subjects with thalassemia. Further studies should
be performed to clarify the optimal approach to these
patients, who are already undergoing a large number of
invasive clinical procedures. Our study showed that the
ability of QUS to detect thalassemic patients with prevalent
fragility fractures is comparable to that of DXA. In fact
hypogonadism, hypothyroidism, HBV, and the presence of
previous fragility fractures (but not diabetes) were sig-
niﬁcantly associated with the demineralization status (lower
T scores values) both with DXA and QUS.
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